Appetite Regulation and Mycoprotein

Not Applicable

Completed

• Conditions: Appetite; Energy Intake
• Interventions: Dietary Supplement: mycoprotein; Dietary Supplement: control protein

• Registration Number: NCT02053025
• Lead Sponsor: Imperial College London

Brief Summary

The purpose of this study is to investigate the effect of eating various levels of mycoprotein (Quorn) on feelings of appetite, energy intake and levels of gut hormones in overweight volunteers.

Detailed Description

Owing to its relatively high protein and fibre content, mycoprotein presents an attractive food product to improve appetite regulation and postprandial glycaemic and insulin responses in overweight and obese individuals at risk of developing T2DM

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2010-03
• Primary Completion: 2012-10
• Study Completion: 2012-10
• Study First Submitted: 2014-01-22
• Study First Submitted QC: 2014-01-31
• Study First Posted: 2014-02-03
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-14
• Last Update Posted: 2019-10-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

• Males and females between the ages of 18 and 65
• body mass index (BMI) 25-32kg/m2
• Weight stable over the past 6 months
• No known major illness or eating disorder nor on any medication that may impact on appetite or hormone levels.
• No paracetamol or other analgesic in the previous 48 hours
• A score of <2.5 in the Dutch Eating Behaviour Questionnaire (DEBQ)
• A score of <2 in the SCOFF questionnaire

Read More

Exclusion Criteria

• Persons outside the age and BMI ranges stated above
• Pregnant and lactating women
• Weight variation of greater than 5% in the last 6 months
• Any diagnosed major illness
• Any paracetamol or analgesic intake in the last 48 hours
• Diagnosed eating disorder
• Allergy to mycoprotein or mushrooms
• Regular consumption of Quorn products
• Dislike of any of the test foods or drinks
• A score of >2.5 in the Dutch Eating Behaviour questionnaire
• A score of 2 or more in the SCOFF questionaire

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
mycoprotein	mycoprotein	3 levels of mycoprotein will be consumed
control protein	control protein	3 levels of a control protein will be consumed

Primary Outcome Measures

Name	Time	Method
Energy intake at ad-libitum meal	upon completion of all participants, expected timeframe: 2 years	Energy intake will be assessed during an ad-libitum meal at 180 minutes at the end of each study visit. Participants will be offered a meal in excess and asked to eat until they feel comfortably full. The meal will be weighed before and after consumption and energy intake will be calculated from the manufacturer's reported nutritional composition.

Secondary Outcome Measures

Name	Time	Method
Glucagon-like peptide-1 (GLP-1)	upon completion of all participants, expected at 2 years	Plasma glucagon-like peptide-1 (GLP-1) concentrations will be measured by radioimmunoassay (RIA) at the end of the study
peptide tyrosine-tyrosine (PYY) levels	upon completion of all participants, expected at 2 years	Plasma peptide tyrosine-tyrosine (PYY) concentrations will be measured by radioimmunoassay (RIA) at the end of the study

Trial Locations

Locations (1)

Imperial College NIHR CRF; 🇬🇧 London, United Kingdom